TemozolomideDNA methylating, chemotherapeutic agent |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 99.62%
- COA (Certificate Of Analysis)
- HPLC
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
Cell experiment [1]: | |
Cell lines | SK-LMS-1 leiomyosarcoma (MGMT-/p53+), Ewing sarcoma A-673 and GIST-T1 (both lines with MGMT+/p53- phenotype), and glioblastoma T98G (MGMT+/p53+) |
Preparation method | The solubility of this compound in DMSO is >6.6mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 62.5, 125, 250 and 500 μM; 72 h |
Applications | In SK-LMS-1 cells, Temozolomide inhibited proliferative activity of SK-LMS-1 cells. A-673 cells was most sensitive to temozolomide, the effect was time- and dose-dependent. Preincubation of Ewing sarcoma cells with O6-benzylguanine potentiated the cytotoxic effect of the alkylating agent and reduced viability of tumor cells. GIST-T1 cells were insensitive to temozolomide. |
Animal experiment [2]: | |
Animal models | PARP1 wild‐type (WT) and PARP1 knock‐out (KO) mice |
Dosage form | 68 mg/kg; once daily for 5 days; orally administrated |
Application | In PARP1 WT mice, temozolomide significantly lowered concentrations of NAD+ in the liver when compared with the control group (by 22%, p = 0.02). In the livers of PARP1 KO mice, there was also a statistically significant reduction in NAD+ in the temozolomide‐only group when compared with the control (by 22%, p = 0.03). |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1] Khusnutdinov RR1, Boichuk SV2. Mechanisms of Sensitivity of Soft Tissue Sarcoma Cells to Temozolomide. Bull Exp Biol Med. 2017 Jul 18. [2]. Almeida GS1, Bawn CM1, Galler M1, et al. PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS. NMR Biomed. 2017 May 22. |
Temozolomide Dilution Calculator
calculate
Temozolomide Molarity Calculator
calculate
Cas No. | 85622-93-1 | SDF | Download SDF |
Chemical Name | 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide | ||
Canonical SMILES | CN1C(=O)N2C=NC(=C2N=N1)C(=O)N | ||
Formula | C6H6N6O2 | M.Wt | 194.15 |
Solubility | ≥29.61mg/mL in DMSO | Storage | Store at -20°C |
Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |